Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Viktoras Frismantas, Maria Pamela Dobay, Anna Rinaldi...
https://pubmed.ncbi.nlm.nih.gov/28122742Actively Recruiting
Age: 0 - 40Years
All Genders
ID06550102
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Led by University Children's Hospital, Zurich · Updated on 2024-08-15
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating drug response profiling (DRP) in children and adults under 40 with blood cancers such as leukemia, myeloma, or lymphoma. This observational study aims to evaluate the feasibility of real-time drug sensitivity testing on patient cancer cells to help identify personalized treatment options, especially for patients with refractory disease. The research integrates drug response data with genetic information to better understand cancer dependencies. The study analyzes primary cancer cells taken during routine diagnostics. These cells are grown with supporting cells and exposed to various drugs, including conventional chemotherapies and targeted agents. Automated microscopy captures detailed cell images, which are analyzed to measure drug effects on cell viability. Drug responses are then compared to clinical outcomes and genetic markers to assess their relevance for treatment decisions. Participants contribute tumor samples and clinical data, which are combined with laboratory tests measuring drug sensitivity and genetic features. Researchers track responses to treatments over time, including minimal residual disease assessments. The main outcome is determining whether real-time drug profiling can be performed within 10 days. The study also monitors how this data can be translated to clinical care over one month, involving collaboration with international leukemia research networks.
CONDITIONS
Brief Title
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Who Can Participate
Age: 0 - 40Years
All Genders
Eligibility Criteria
You may qualify if you...
- Pediatric and adult patients below the age of 40 years
- Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
- Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research
- Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.
You will not qualify if you...
- Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Approximately 10 days
Tumor material is collected as part of routine diagnostics and donated for translational research to assess drug sensitivity of primary leukemia cells ex vivo.
1 visit (in-person) for tumor material collection
Long-term Monitoring
Duration - Up to 1 month
Participants are observed as drug response profiles are correlated to clinical response and integrated with molecular and cytogenetic data collected from treating clinics.
Trial Site Locations
Total: 1 location
1
University Children's Hospital Zurich
Zurich, Canton of Zurich, Switzerland, 8032
Actively Recruiting
Loading map...
Research Team
J
Jean-Pierre Bourquin, MD, PhD
F
Fabio Steffen, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here